# US 2025/0082693 A1 · Ammonia oxidizing microorganisms for use and delivery to the visual and auditory systems

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082693 A1
- Document ID: US20250082693A1
- Status: Published application
- Kind: A1
- Application number: 18/957,655
- Filed: 2024-11-22
- Published: 2025-03-13
- Earliest claimed: 2017-07-18
- Assignees: Aobiome LLC
- Applicants: Aobiome LLC
- Inventors: Todd Krueger; Larry Weiss
- Web page: https://patentgrep.com/patent/US20250082693A1

## CPC

- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61P 37/00: Drugs for immunological or allergic disorders
- A61K 8/64: Proteins; Peptides; Derivatives or degradation products thereof
- A61K 8/99: from microorganisms other than algae or fungi, e.g. protozoa or bacteria
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 9/12: Aerosols; Foams {(A61K9/0043, A61K9/0056, A61K9/006, A61K9/0073 take precedence; spray-films A61K9/7015)}
- A61K 9/2004: {Excipients; Inactive ingredients}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K 47/02: Inorganic compounds
- A61Q 19/00: Preparations for care of the skin
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0043: {Nose}
- A61K 9/0046: {Ear}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

Ammonia oxidizing microorganism preparations for delivery to the visual and auditory systems, kits including ammonia oxidizing preparations for delivery to the visual and auditory systems, and devices for administering ammonia oxidizing preparations to the visual and auditory systems are provided. Methods of introducing ammonia oxidizing microorganisms to the eye are provided. Methods of introducing ammonia oxidizing microorganisms to the ear are provided. Methods of treating disorders, including eye disorders, ear disorders, and inflammatory disorders, with ammonia oxidizing microorganism preparations are provided.

## Claims

### Claim 1

A method of introducing ammonia oxidizing microorganisms (AOM) to a subject, comprising:
administering a preparation comprising AOM to an ear of the subject.

### Claim 2

A method of introducing ammonia oxidizing microorganisms (AOM) to a subject, comprising:
administering a preparation comprising AOM to an eye of the subject via topical or intravitreal delivery.

### Claim 3

The method of any of the preceding claims, wherein the preparation is administered topically.

### Claim 4

The method of any of the preceding claims, wherein administration is substantially noninvasive.

### Claim 5

The method of any of the preceding claims, wherein an effective amount of the preparation is administered to a target tissue of the ear of the subject.

### Claim 6

The method of any of the preceding claims, wherein an effective amount of the preparation is administered to a target tissue of the eye of the subject.

### Claim 7

The method of any of the preceding claims, wherein the preparation is administered, e.g., topically applied, to a first tissue, e.g. a deposit tissue.

### Claim 8

The method of any of the preceding claims, wherein the first tissue is the target tissue.

### Claim 9

The method of any of the preceding claims, wherein the first tissue is other than the target tissue, e.g., the preparation is applied to a first tissue and the preparation, or a product of the preparation, e.g., NO, is transported, e.g., by diffusion, to a second tissue, e.g. the target tissue.

### Claim 10

The method of any of the preceding claims, wherein a deposit tissue, target tissue, or both is an outer ear tissue, inner ear tissue, external auditory canal, internal auditory canal, tympanic membrane, tympanic cavity, malleus, incus, auditory tube, Eustachian tube, round window, oval window, ossicle, labyrinth, vestibule, utricle, saccule, staple, cochlea, canal, semicircular canal, temporal bone, vestibular nerve, or cochlear nerve.

### Claim 11

The method of any of the preceding claims, wherein a deposit tissue, target tissue, or both relates to an intravitreous tissue, posterior chamber, or another chamber of the eye of the subject.

### Claim 12

The method of any of the preceding claims, wherein a deposit tissue, target tissue, or both is an eyelid, e.g., inner eyelid, retina, ocular globe, orbit, optic disk, optic nerve, vitreous humor, intrascleral, subconjunctiva, lens, ciliary body, iris, pupil, cornea, conjunctiva, sclera, topical tissue, or proximate tissue of the eye of the subject.

### Claim 13

The method of any of the preceding claims, wherein the target tissue is associated with a desired local effect.

### Claim 14

The method of any of the preceding claims, wherein the target tissue is associated with a desired systemic effect.

### Claim 15

The method of any of the preceding claims, wherein administering results in improved hearing, reduced ear ache, reduced ear infection, reduced pruritus, or reduced tinnitus in the subject.

### Claim 16

The method of any of the preceding claims, wherein administering results in reduced vertigo, dizziness or nausea for the subject.

### Claim 17

The method of any of the preceding claims, wherein the desired local effect involves treatment of a periocular condition, e.g., blepharitis, dry eye, itching, inflammation, wound healing, intraocular diseases, e.g., macular degeneration, infections, and ocular blood pressure, e.g., glaucoma, elevated intraocular pressure, ocular hypertension, and ocular hypotension.

### Claim 18

The method of any of the preceding claims, wherein the desired systemic effect involves treatment of one or more of headaches, cardiovascular diseases, inflammation, immune responses and autoimmune disorders, liver diseases, mitochondrial diseases, infections, neurological diseases, psychiatric disorders, nitric oxide disorders, urea cycle disorders, congestion, vasodilation disorders, skin diseases, wound healing, reactions to insect bites, connective tissue disorders, and certain viral, bacterial, and fugal infections.

### Claim 19

A method of treating an ear disorder in a subject, comprising:
administering an effective amount of preparation comprising ammonia oxidizing microorganism (AOM) to the subject,
thereby treating the ear disorder.

### Claim 20

The method of any of the preceding claims, wherein the ear disorder involves vertigo, swimmer's ear, pruritus, or tinnitus.

### Claim 21

The method of any of the preceding claims, wherein the ear disorder comprises an inflammatory condition, a bacterial, viral, or fungal infection, or a congenital abnormality.

### Claim 22

A method of treating an inflammatory eye disorder in a subject, comprising:
administering to the subject an effective amount of a preparation comprising AOM,
thereby treating the inflammatory eye disorder.

### Claim 23

The method of any of the preceding claims, wherein the inflammatory eye disorder comprises dry eye or Meibomian Gland Dysfunction (MGD).

### Claim 24

The method of any of the preceding claims, wherein the inflammatory eye disorder comprises blepharitis.

### Claim 25

The method of any of the preceding claims, wherein the inflammatory eye disorder comprises a disorder of the back of the eye, e.g., of the retina, e.g., macular degeneration.

### Claim 26

The method of any of the preceding claims, wherein the inflammatory eye disorder is associated with intraocular pressure, e.g., elevated intraocular pressure.

### Claim 27

The method of any of the preceding claims, wherein the inflammatory eye disorder comprises an infectious disorder.

### Claim 28

The method of any of the preceding claims, wherein the inflammatory eye disorder comprises a bacterial, fungal, or viral infection, e.g., of the ocular globe or other eye tissue.

### Claim 29

The method of any of the preceding claims, wherein the inflammatory eye disorder is characterized by or comprises sty or chalazion formation.

### Claim 30

The method of any of the preceding claims, wherein the inflammatory eye disorder comprises an allergy.

### Claim 31

The method of any of the preceding claims, wherein administering is device-assisted.

### Claim 32

The method of any of the preceding claims, wherein administering the effective amount of the preparation promotes endothelial function.

### Claim 33

The method of any of the preceding claims, wherein administering the effective amount of the preparation promotes lubrication or hydration of the eye.

### Claim 34

The method of any of the preceding claims, wherein administering the effective amount of the preparation changes or alters a level of nitrite or NO in the subject, e.g. at the target tissue or in circulation.

### Claim 35

The method of any of the preceding claims, wherein administering the effective amount of the preparation changes or alters a level of nitrite or NO in the subject, e.g. at a target tissue of the eye.

### Claim 36

The method of any of the preceding claims, wherein administering the effective amount of the preparation changes or alters a level of nitrite or NO in the subject, e.g. at a target tissue of the ear.

### Claim 37

The method of any of the preceding claims, wherein administering the effective amount of the preparation modulates a microbiome associated with the subject.

### Claim 38

The method of any of the preceding claims, wherein administering the effective amount of the preparation modulates a microbiome associated with the eye of the subject.

### Claim 39

The method of any of the preceding claims, wherein administering the effective amount of the preparation modulates a microbiome associated with the ear of the subject.

### Claim 40

The method of any of the preceding claims, wherein the preparation is administered prior to onset of an ear disorder.

### Claim 41

The method of any of the preceding claims, wherein the preparation is administered during incidence of an ear disorder.

### Claim 42

The method of any of the preceding claims, wherein the preparation is administered subsequent to the subsiding of an ear disorder.

### Claim 43

The method of any of the preceding claims, wherein the preparation is administered in response to a trigger, warning sign, or symptom of an ear disorder.

### Claim 44

The method of any of the preceding claims, wherein the preparation is administered prior to onset of the inflammatory eye disorder.

### Claim 45

The method of any of the preceding claims, wherein the preparation is administered during incidence of the inflammatory eye disorder.

### Claim 46

The method of any of the preceding claims, wherein the preparation is administered subsequent to the subsiding of the inflammatory eye disorder.

### Claim 47

The method of any of the preceding claims, wherein the preparation is administered in response to a trigger, warning sign, or symptom of the inflammatory eye disorder.

### Claim 48

The method of any of the preceding claims, further comprising determining whether the subject is in need of treatment for an ear disorder.

### Claim 49

The method of any of the preceding claims, further comprising determining whether the subject is in need of treatment for the inflammatory eye disorder.

### Claim 50

The method of any of the preceding claims, wherein the preparation is administered as a solution, suspension, liquid, ointment, gel, hydrogel, emulsion, or insert.

### Claim 51

The method of any of the preceding claims, wherein the preparation is administered as a spray, aerosol, or mist.

### Claim 52

The method of any of the preceding claims, wherein the preparation is administered as a droplet or wash.

### Claim 53

The method of any of the preceding claims, wherein the preparation is formulated to be substantially bio-compatible.

### Claim 54

The method of any of the preceding claims, wherein the preparation is formulated to be compatible with the eye of the subject.

### Claim 55

The method of any of the preceding claims, wherein the preparation is substantially isotonic.

### Claim 56

The method of any of the preceding claims, wherein the preparation has a substantially physiological pH level.

### Claim 57

The method of any of the preceding claims, wherein the preparation has a substantially physiological pH level, e.g., a pH level between about 7.14 and about 7.82.

### Claim 58

The method of any of the preceding claims, wherein the preparation has an osmolarity of between about 100 mOsmol/L and about 640 mOsmol/L.

### Claim 59

The method of any of the preceding claims, wherein the preparation has a surface tension of between about 43 nN/m and about 47 nN/m.

### Claim 60

The method of any of the preceding claims, wherein the preparation is formulated to resemble tears of the subject.

### Claim 61

The method of any of the preceding claims, wherein the preparation is formulated for immediate release or extended release.

### Claim 62

The method of any of the preceding claims, wherein the preparation or product thereof is formulated to penetrate and otherwise reach a target eye tissue.

### Claim 63

The method of any of the preceding claims, wherein the preparation or product thereof is formulated to permeate or be absorbed through the cornea.

### Claim 64

The method of any of the preceding claims, wherein the preparation or product thereof is formulated to penetrate and otherwise reach a target ear tissue.

### Claim 65

The method of any of the preceding claims, wherein the preparation is formulated to deliver nitrite or NO to a target tissue, locally or systemically.

### Claim 66

The method of any of the preceding claims, wherein the preparation is formulated for transmucosal delivery and/or circulation, e.g. locally or systemically.

### Claim 67

The method of any of the preceding claims, wherein the preparation or product thereof is formulated to be delivered for systemic circulation.

### Claim 68

The method of any of the preceding claims, further comprising administering a second amount of the preparation to the subject.

### Claim 69

The method of any of the preceding claims, wherein the preparation is administered as part of a combination therapy.

### Claim 70

The method of any of the preceding claims, further comprising administering a second treatment in combination with the preparation.

### Claim 71

The method of any of the preceding claims, wherein the second treatment comprises a surgical procedure.

### Claim 72

The method of any of the preceding claims, wherein the preparation is administered for a period of time prior to initiating the second treatment.

### Claim 73

The method of any of the preceding claims, wherein the preparation is administered concurrently with the second treatment.

### Claim 74

The method of any of the preceding claims, wherein the preparation is administered for a period of time subsequent to ceasing the second treatment.

### Claim 75

The method of any of the preceding claims, wherein the second treatment is administered via an alternate mode of administration, e.g. orally or intranasally.

### Claim 76

The method of any of the preceding claims, wherein the second treatment is administered to the eye, e.g., topically or intravitreally, or via an alternate mode of administration, e.g., orally or intranasally.

### Claim 77

The method of any of the preceding claims, wherein the subject has a therapeutic level of a second treatment.

### Claim 78

The method of any of the preceding claims, wherein the preparation is administered in conjunction with one or more ophthalmic ion-exchange formulations, chelators, penetration enhancers, e.g., transporter-target prodrugs, ultrasound, soft drugs, mucoadhesives, or steam, e.g., warm compress.

### Claim 79

The method of any of the preceding claims, wherein the preparation is administered in conjunction with nitrite, nitrate, and/or NO.

### Claim 80

The method of any of the preceding claims, wherein the effective amount is a therapeutically effective dose of AOM.

### Claim 81

The method of any of the preceding claims, wherein the therapeutically effective dose of AOM is about or greater than about 1×103, 104, 105, 106, 107, 108, 109, 1010, 1011, 1012, 1013, or 1014 CFU.

### Claim 82

The method of any of the preceding claims, wherein the preparation is administered as an analgesic.

### Claim 83

The method of any of the preceding claims, wherein the preparation is administered as a prophylactic.

### Claim 84

The method of any of the preceding claims, wherein the preparation is self-administered.

### Claim 85

The method of any of the preceding claims, wherein the preparation is administered about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 times per day.

### Claim 86

The method of any of the preceding claims, wherein the preparation is administered for about 1-3, 3-5, 5-7, 7-9, 5-10, 10-14, 12-18, 12-21, 21-28, 28-35, 35-42, 42-49, 49-56, 46-63, 63-70, 70-77, 77-84, or 84-91 days.

### Claim 87

The method of any of the preceding claims, wherein the preparation is administered within 30, 60, 90, 120, 150, or 180 minutes of the subject waking from sleep.

### Claim 88

The method of any of the preceding claims, wherein the preparation is administered within 30, 60, 90, 120, 150, or 180 minutes prior to the subject sleeping.

### Claim 89

The method of any of the preceding claims, wherein the preparation is administered within 30, 60, 90, 120, 150, or 180 minutes of the subject eating.

### Claim 90

The method of any of the preceding claims, wherein the preparation is administered 30, 60, 90, 120, 150, or 180 minutes before the subject cleanses or showers.

### Claim 91

The method of any of the preceding claims, wherein the subject is female.

### Claim 92

The method of any of the preceding claims, wherein the subject is male.

### Claim 93

The method of any of the preceding claims, wherein the subject is characterized as one of the following ethnicity/race: Asian, black or African American, Hispanic or Latino, white, or multi-racial.

### Claim 94

The method of any of the preceding claims, wherein the subject is of an age of less than 1, or between 1-5, 5-10, 10-20, 20-30, 30-40, 40-50, 50-60, or over 60 years.

### Claim 95

The method of any of the preceding claims, wherein the preparation comprises AOM in a buffer solution, e.g., an aqueous buffer solution.

### Claim 96

The method of any of the preceding claims, wherein the buffer solution, e.g., aqueous buffer solution, comprises disodium phosphate and magnesium chloride, for example, 50 mM Na2HPO4 and 2 mM MgCl2 in water.

### Claim 97

The method of any of the preceding claims, wherein the buffer solution e.g., aqueous buffer solution, consisting essentially of disodium phosphate and magnesium chloride, for example, 50 mM Na2HPO4 and 2 mM MgCl2 in water.

### Claim 98

The method of any of the preceding claims, wherein the buffer solution, e.g., aqueous buffer solution, consists of disodium phosphate and magnesium chloride, for example, 50 mM Na2HPO4 and 2 mM MgCl2 in water.

### Claim 99

The method of any of the preceding claims, wherein the preparation comprises at least one of ammonia, ammonium salts, and urea.

### Claim 100

The method of any of the preceding claims, wherein the preparation comprises a controlled release material, e.g., slow release material.

### Claim 101

The method of any of the preceding claims, wherein the preparation further comprises an excipient, e.g., a pharmaceutically acceptable excipient.

### Claim 102

The method of any of the preceding claims, wherein the excipient comprises at least one of water, hydrogen peroxide, mineral oil, vegetable oil, glycerin, anhydrous glycerin, propylene glycol, aluminum acetate, isopropyl alcohol, and ethanol.

### Claim 103

The method of any of the preceding claims, wherein the excipient comprises an absorption and penetration enhancer, preservative, antioxidant, buffer, chelating agent, ion exchange agent, solubilizing agent, suspending agent, thickener, surfactant, wetting agent, tonicity-adjusting agent, and a vehicle for proper drug delivery.

### Claim 104

The method of any of the preceding claims, wherein the excipient comprises a surfactant.

### Claim 105

The method of any of the preceding claims, wherein the preparation further comprises at least one of an analgesic agent, a chelator, a hygroscopic agent, a ceramide disrupting agent, an anti-inflammatory agent, an anti-infective agent, a reacidifying agent, and a vehicle.

### Claim 106

The method of any of the preceding claims, wherein the preparation is substantially free of other organisms.

### Claim 107

The method of any of the preceding claims, wherein the preparation comprises between about 1×103 CFU/mL to about 1×1014 CFU/mL AOM.

### Claim 108

The method of any of the preceding claims, wherein the preparation comprises between about 1×109 CFU/mL to about 10×109 CFU/mL AOM.

### Claim 109

The method of any of the preceding claims, wherein the preparation is administered before or after a surgical or diagnostic procedure.

### Claim 110

The method of any of the preceding claims, wherein the AOM comprise ammonia oxidizing bacteria (AOB).

### Claim 111

The method of any of the preceding claims, wherein the AOM consist essentially of AOB.

### Claim 112

The method of any of the preceding claims, wherein the AOM consist of AOB.

### Claim 113

The method of any of the preceding claims, wherein the AOM comprise Nitrosomonas, Nitrosococcus, Nitrosospira, Nitrosocystis, Nitrosolobus, Nitrosovibrio, and combinations thereof.

### Claim 114

The method of any of the preceding claims, wherein the AOM is Nitrosomonas eutropha (N. eutropha).

### Claim 115

The method of any of the preceding claims, wherein the AOM is N. eutropha D23, having ATCC accession number PTA-121157.

### Claim 116

The method of any of the preceding claims, wherein the AOM comprise ammonia oxidizing archaea (AOA).

### Claim 117

The method of any of the preceding claims, wherein the AOM are capable of converting ammonia or ammonium to nitrite at a rate of at least about 1 pmol/min/mg protein, e.g., at least about 0.1 nmol/min/mg protein.

### Claim 118

The method of any of the preceding claims, wherein a target percentage of administered AOM are transferred to the ear of the subject.

### Claim 119

The method of any of the preceding claims, wherein the preparation is administered in conjunction with an anti-inflammatory agent.

### Claim 120

The method of any of the preceding claims, wherein the preparation is administered in conjunction with a medical approach that treats, e.g., is approved to treat or is commonly used to treat, the relevant disease or disorder, or a symptom of the relevant disease or disorder.

### Claim 121

The method of any of the preceding claims, wherein the subject has a disrupted microbiome.

### Claim 122

The method of any of the preceding claims, wherein the preparation further comprises or is administered concurrently with a compound that promotes growth or metabolism of the AOM, NO production, and/or urease activity.

### Claim 123

The method of any of the preceding claims, wherein a biome-friendly product is used in connection with the administered preparation comprising AOM.

### Claim 124

A preparation comprising AOM, as recited in any of the preceding claims, for administration to an ear of a subject.

### Claim 125

A preparation comprising AOM, as recited in any of the preceding claims, for treatment of an ear disorder in a subject.

### Claim 126

A preparation comprising AOM, as recited in any of the preceding claims, for treatment of an inflammatory eye disorder in a subject.

### Claim 127

The preparation of any of the preceding claims, wherein the preparation is packaged for single use.

### Claim 128

The preparation of any of the preceding claims, wherein the preparation is packaged for multiple use.

### Claim 129

The preparation of any of the preceding claims, comprising AOM and other organisms, e.g., a community of organisms.

### Claim 130

A device for administering a preparation comprising AOM, as recited in any of the preceding claims, to an ear of a subject.

### Claim 131

A device for administering a preparation comprising AOM, as recited in any of the preceding claims, to an eye of a subject.

### Claim 132

A device configured to administer a preparation comprising AOM, as recited in any of the preceding claims, to an ear of a subject.

### Claim 133

A device configured to administer a preparation comprising AOM, as recited in any of the preceding claims, to an eye of a subject.

### Claim 134

A kit comprising a preparation comprising AOM as recited in any of the preceding claims.

### Claim 135

The kit of any of the preceding claims, further including instructions for use.
